Developing a vaccine to combat antibiotic-resistant E. coli infections
ExPEC Vaccine Development
This study is working on a new vaccine to help protect people from serious infections caused by a harmful type of E. coli that can lead to antibiotic resistance, and it aims to find a way to keep you safe from these infections in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11125016 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine to protect against extraintestinal pathogenic E. coli (ExPEC), a major cause of antibiotic resistance and related mortality. By analyzing over 20,000 strains of this bacterium, researchers have identified key virulence factors that could be targeted for vaccine development. The project will involve pre-clinical studies to test the vaccine's effectiveness in preventing various types of ExPEC infections, optimizing vaccine parameters, and exploring innovative adjuvants to enhance immune response. Patients may benefit from a new preventive measure against serious infections caused by this dangerous pathogen.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for infections caused by antibiotic-resistant bacteria, particularly those with compromised immune systems or underlying health conditions.
Not a fit: Patients who are not at risk for infections caused by E. coli or those who do not have underlying health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of life-threatening infections caused by antibiotic-resistant E. coli.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting antibiotic-resistant bacteria, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Maresso, Anthony W — Baylor College of Medicine
- Study coordinator: Maresso, Anthony W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.